<H1>Chapter DOI: 10.1208/aapsj070364<br/>Cited-By Count: 86</H1><table border="1" width="30%"><tr><td>Total References</td><td>219</td></tr><tr><td>Springer references</td><td>15</td></tr><tr><td>Non Springer references</td><td>204</td></tr><tr><td>BibStructured Count</td><td width="10%">216</td></tr><tr><td>BibUnstructured Count</td><td width="10%">3</td></tr><tr><td>DOI already available in SpringerLink</td><td>181</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>10</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>10</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>10</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>6</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.<Emphasis Type="Italic">Pharmacol Rev.</Emphasis> 2002;54:161&#8211;202.</td><td><a href=http://dx.doi.org/10.1124/pr.54.2.161>10.1124/pr.54.2.161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibChapter</td><td>Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:1&#8211;51.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA.<Emphasis Type="Italic">Nature</Emphasis>. 1990;346:561&#8211;564.</td><td><a href=http://dx.doi.org/10.1038/346561a0>10.1038/346561a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids.<Emphasis Type="Italic">Nature</Emphasis>. 1993;365:61&#8211;65.</td><td><a href=http://dx.doi.org/10.1038/365061a0>10.1038/365061a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Pertwee RG. Pharmacology of cannabinoid receptor ligands.<Emphasis Type="Italic">Curr Med Chem</Emphasis>. 1999;6:635&#8211;664.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB<Subscript>1</Subscript> receptors.<Emphasis Type="Italic">Life Sci.</Emphasis> 2005;76:1307&#8211;1324.</td><td><a href=http://dx.doi.org/10.1016/j.lfs.2004.10.025>10.1016/j.lfs.2004.10.025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Pertwee RG. Novel pharmacological targets for cannabinoids.<Emphasis Type="Italic">Curr Neuropharmacol</Emphasis>. 2004;2:9&#8211;29.</td><td><a href=http://dx.doi.org/10.2174/1570159043476927>10.2174/1570159043476927</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Price MRBaillie GThomas</span> <span style='background:#DDDDDD'>A.</span></span></aug> <span style='background:#FFD9B3'>Allosteric modulation of the cannabinoid &lt;Subscript&gt;CB1&lt;/Subscript&gt; receptor. <i>Mol Pharmacol</i></span>. <span style='background:#FFFF49'>In press</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Bradshaw HB, Walker JM. The expanding field of cannabimimetic and related lipid mediators.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2005;144:459&#8211;465.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0706093>10.1038/sj.bjp.0706093</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Steffens M, Zentner J, Honegger J, Feuerstein TJ. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB<Subscript>1</Subscript> receptor.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2005;69:169&#8211;178.</td><td><a href=http://dx.doi.org/10.1016/j.bcp.2004.08.033>10.1016/j.bcp.2004.08.033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibChapter</td><td>Cabral GA, Staab A. Effects on the immune system. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:385&#8211;423.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibChapter</td><td>Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:327&#8211;365.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibChapter</td><td>Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:367&#8211;383.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide,<Emphasis Type="Italic">N</Emphasis>-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2004;141:1118&#8211;1130.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705711>10.1038/sj.bjp.0705711</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Baker CL, McDougall JJ. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2004;142:1361&#8211;1367.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705902>10.1038/sj.bjp.0705902</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibChapter</td><td>Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Pertwee RG, ed.<Emphasis Type="Italic">Camabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:147&#8211;185.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Bisogno T, Melck D, Bobrov MY, et al.<Emphasis Type="Italic">N</Emphasis>-acyl-dopamines: novel synthetic CB<Subscript>1</Subscript> cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity<Emphasis Type="Italic">in vitro</Emphasis> and<Emphasis Type="Italic">in vivo</Emphasis>.<Emphasis Type="Italic">Biochem J.</Emphasis> 2000;351:817&#8211;824.</td><td><a href=http://dx.doi.org/10.1042/0264-6021:3510817>10.1042/0264-6021:3510817</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Leggett JD, Aspley S, Beckett SRG, D&#8217;Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB<Subscript>1</Subscript> cannabinoid receptors.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2004;141:253&#8211;262.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705607>10.1038/sj.bjp.0705607</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Porter AC, Sauer J-M, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB<Subscript>1</Subscript> receptor.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;301:1020&#8211;1024.</td><td><a href=http://dx.doi.org/10.1124/jpet.301.3.1020>10.1124/jpet.301.3.1020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior.<Emphasis Type="Italic">J Neurobiol</Emphasis>. 2004;61:149&#8211;160.</td><td><a href=http://dx.doi.org/10.1002/neu.20080>10.1002/neu.20080</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2003;140:802&#8211;808.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705468>10.1038/sj.bjp.0705468</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Ueda N. Endocannabinoid hydrolases.<Emphasis Type="Italic">Prostaglandins Other Lipid Mediat</Emphasis>. 2002;68&#8211;9:521&#8211;534.</td><td><a href=http://dx.doi.org/10.1016/S0090-6980(02)00053-9>10.1016/S0090-6980(02)00053-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibChapter</td><td>Ho W-SV, Hillard CJ. Modulators of endocannabinoid enzymic hydrolysis and membrane transport. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:187&#8211;207.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of 2 endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2004;20:441&#8211;458.</td><td><a href=http://dx.doi.org/10.1111/j.1460-9568.2004.03428.x>10.1111/j.1460-9568.2004.03428.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for<Emphasis Type="Italic">N</Emphasis>-palmitoylethanolamine, a putative endogenous anti-inflammatory substance.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:35552&#8211;35557.</td><td><a href=http://dx.doi.org/10.1074/jbc.M106261200>10.1074/jbc.M106261200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide.<Emphasis Type="Italic">Cell Mol Life Sci</Emphasis>. 2005;62:708&#8211;716.</td><td><a href=http://dx.doi.org/10.1007/s00018-004-4494-0>10.1007/s00018-004-4494-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3&#8242;-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2005;313:352&#8211;358.</td><td><a href=http://dx.doi.org/10.1124/jpet.104.078980>10.1124/jpet.104.078980</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids.<Emphasis Type="Italic">Prostaglandins Leukot Essent Fatty Acids</Emphasis>. 2002;66:211&#8211;220.</td><td><a href=http://dx.doi.org/10.1054/plef.2001.0359>10.1054/plef.2001.0359</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Saario SM, Savinainen JR, Laitinen JT, J&#228;rvinen T, Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2004;67:1381&#8211;1387.</td><td><a href=http://dx.doi.org/10.1016/j.bcp.2003.12.003>10.1016/j.bcp.2003.12.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2004;66:1260&#8211;1264.</td><td><a href=http://dx.doi.org/10.1124/mol.104.002071>10.1124/mol.104.002071</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues.<Emphasis Type="Italic">FEBS Lett</Emphasis>. 2002;513:294&#8211;298.</td><td><a href=http://dx.doi.org/10.1016/S0014-5793(02)02341-4>10.1016/S0014-5793(02)02341-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors.<Emphasis Type="Italic">FEBS Lett</Emphasis>. 2001;506:253&#8211;256.</td><td><a href=http://dx.doi.org/10.1016/S0014-5793(01)02934-9>10.1016/S0014-5793(01)02934-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1997;40:659&#8211;667.</td><td><a href=http://dx.doi.org/10.1021/jm960752x>10.1021/jm960752x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Fernando SR, Pertwee RG. Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 1997;121:1716&#8211;1720.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0701303>10.1038/sj.bjp.0701303</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Savinainen JR, Saario SM, Niemi R, J&#228;rvinen T, Laitinen JT. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A<Subscript>1</Subscript> and cannabinoid CB<Subscript>1</Subscript> receptors.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2003;140:1451&#8211;1459.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705577>10.1038/sj.bjp.0705577</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Nithipatikom K, Endsley MP, Isbell MA, et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2004;64:8826&#8211;8830.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-3136>10.1158/0008-5472.CAN-04-3136</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hyyrolysis.<Emphasis Type="Italic">Nat Med</Emphasis>. 2003;9:76&#8211;81.</td><td><a href=http://dx.doi.org/10.1038/nm803>10.1038/nm803</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Lichtman AH, Leung D, Shelton CC, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;311:441&#8211;448.</td><td><a href=http://dx.doi.org/10.1124/jpet.104.069401>10.1124/jpet.104.069401</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Huang SM, Bisogno T, Petros TJ, et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:42639&#8211;42644.</td><td><a href=http://dx.doi.org/10.1074/jbc.M107351200>10.1074/jbc.M107351200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Bisogno T, Melck D, De Petrocellis L, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 1998;248:515&#8211;522.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1998.8874>10.1006/bbrc.1998.8874</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth.<Emphasis Type="Italic">Gastroenterology</Emphasis>. 2003;125:677&#8211;687.</td><td><a href=http://dx.doi.org/10.1016/S0016-5085(03)00881-3>10.1016/S0016-5085(03)00881-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Jonsson K-O, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2001;133:1263&#8211;1275.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0704199>10.1038/sj.bjp.0704199</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Khanolkar AD, Abadji V, Lin S, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1996;39:4515&#8211;4519.</td><td><a href=http://dx.doi.org/10.1021/jm960152y>10.1021/jm960152y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition.<Emphasis Type="Italic">Science</Emphasis>. 1997;277:1094&#8211;1097.</td><td><a href=http://dx.doi.org/10.1126/science.277.5329.1094>10.1126/science.277.5329.1094</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ. Structure-activity relationships among<Emphasis Type="Italic">N</Emphasis>-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2000;74:2597&#8211;2606.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2000.0742597.x>10.1046/j.1471-4159.2000.0742597.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Zygmunt PM, Chuang H, Movahed P, Julius D, H&#246;gest&#228;tt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;396:39&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(00)00207-7>10.1016/S0014-2999(00)00207-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity.<Emphasis Type="Italic">FEBS Lett</Emphasis>. 2000;483:52&#8211;56.</td><td><a href=http://dx.doi.org/10.1016/S0014-5793(00)02082-2>10.1016/S0014-5793(00)02082-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Fowler CJ, Tiger G, Ligresti A, L&#243;pez-Rodr&#237;guez ML, Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis&#8212;a difficult issue to handle.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;492:1&#8211;11.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2004.03.048>10.1016/j.ejphar.2004.03.048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2003;65:1473&#8211;1481.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(03)00109-6>10.1016/S0006-2952(03)00109-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>L&#243;pez-Rodr&#237;guez ML, Viso A, Ortega-Guti&#233;rrez S, et al. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.<Emphasis Type="Italic">Eur J Med Chem</Emphasis>. 2003;38:403&#8211;412.</td><td><a href=http://dx.doi.org/10.1016/S0223-5234(03)00045-X>10.1016/S0223-5234(03)00045-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Ruiz-Llorente L, Ortega-Guti&#233;rrez S, Viso A, et al. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2004;141:457&#8211;467.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705628>10.1038/sj.bjp.0705628</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Benito C, N&#250;&#241;ez E, Tol&#243;n RM, et al. Cannabinoid CB<Subscript>2</Subscript> receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer&#8217;s disease brains.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2003;23:11136&#8211;11141.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Ram&#237;rez BG, Bl&#225;zquez C, G&#243;mez del Pulgar T, Guzm&#225;n N, de Ceballos ML. Prevention of Alzheimer&#8217;s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2005;25:1904&#8211;1913.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.4540-04.2005>10.1523/JNEUROSCI.4540-04.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2004;29:2108&#8211;2114.</td><td><a href=http://dx.doi.org/10.1038/sj.npp.1300558>10.1038/sj.npp.1300558</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1999;10:1665&#8211;1669.</td><td><a href=http://dx.doi.org/10.1097/00001756-199906030-00008>10.1097/00001756-199906030-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [<Superscript>3</Superscript>H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.<Emphasis Type="Italic">Neuroscience</Emphasis>. 2001;103:9&#8211;15.</td><td><a href=http://dx.doi.org/10.1016/S0306-4522(00)00552-2>10.1016/S0306-4522(00)00552-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Zavitsanou K, Garrick T, Huang XF. Selective antagonist [<Superscript>3</Superscript>H]SR141716A binding to cannabinoid CB<Subscript>1</Subscript> receptors is increased in the anterior cingulate cortex in schizophrenia.<Emphasis Type="Italic">Prog Neuropsychopharmacol Biol Psychiatry</Emphasis>. 2004;28:355&#8211;360.</td><td><a href=http://dx.doi.org/10.1016/j.pnpbp.2003.11.005>10.1016/j.pnpbp.2003.11.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia.<Emphasis Type="Italic">Lipids Health Dis.</Emphasis> 2003;2:1&#8211;9.</td><td><a href=http://dx.doi.org/10.1186/1476-511X-2-5>10.1186/1476-511X-2-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Hungund BL, Vinod KY, Kassir SA, et al. Upregulation of CB<Subscript>1</Subscript> receptors and agonist-stimulated [<Superscript>35</Superscript>S]GTP&#947;S binding in the prefrontal cortex of depressed suicide victims.<Emphasis Type="Italic">Mol Psychiatry</Emphasis>. 2004;9:184&#8211;190.</td><td><a href=http://dx.doi.org/10.1038/sj.mp.4001376>10.1038/sj.mp.4001376</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Vinod KY, Arango V, Xie S, et al. Elevated levels of endocannabinoids and CB<Subscript>1</Subscript> receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims.<Emphasis Type="Italic">Biol Psychiatry</Emphasis>. 2005;57:480&#8211;486.</td><td><a href=http://dx.doi.org/10.1016/j.biopsych.2004.11.033>10.1016/j.biopsych.2004.11.033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Lastres-Becker I, Cebeira M, de Ceballos ML, et al. Increased cannabinoid CB<Subscript>1</Subscript> receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson&#8217;s syndrome and of MPTP-treated marmosets.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2001;14:1827&#8211;1832.</td><td><a href=http://dx.doi.org/10.1046/j.0953-816x.2001.01812.x>10.1046/j.0953-816x.2001.01812.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Glass M, Faull R, Dragunow M. Loss of cannabinoid receptors in the substantia-nigra in Huntington&#8217;s disease.<Emphasis Type="Italic">Neurosci</Emphasis>. 1993;56:523&#8211;527.</td><td><a href=http://dx.doi.org/10.1016/0306-4522(93)90352-G>10.1016/0306-4522(93)90352-G</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Richfield EK, Herkenham M. Selective vulnerability in Huntington&#8217;s disease: preferential loss of cannabinoid receptors in lateral globus pallidus.<Emphasis Type="Italic">Ann Neurol</Emphasis>. 1994;36:577&#8211;584.</td><td><a href=http://dx.doi.org/10.1002/ana.410360406>10.1002/ana.410360406</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Sch&#228;bitz W-R, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study.<Emphasis Type="Italic">Stroke</Emphasis>. 2002;33:2112&#8211;2114.</td><td><a href=http://dx.doi.org/10.1161/01.STR.0000023491.63693.18>10.1161/01.STR.0000023491.63693.18</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agric&#242; A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage.<Emphasis Type="Italic">Lancet</Emphasis>. 2000;355:1326&#8211;1329.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)02115-2>10.1016/S0140-6736(00)02115-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Maccarrone M, Bisogno T, Valensise H, et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer.<Emphasis Type="Italic">Mol Hum Reprod</Emphasis>. 2002;8:188&#8211;195.</td><td><a href=http://dx.doi.org/10.1093/molehr/8.2.188>10.1093/molehr/8.2.188</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Wang Y, Liu Y, Ito Y, et al. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock.<Emphasis Type="Italic">Anal Biochem</Emphasis>. 2001;294:73&#8211;82.</td><td><a href=http://dx.doi.org/10.1006/abio.2001.5015>10.1006/abio.2001.5015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>B&#225;tkai S, J&#225;rai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB<Subscript>1</Subscript> receptors mediate the vasodilated state in advanced liver cirrhosis.<Emphasis Type="Italic">Nat Med</Emphasis>. 2001;7:827&#8211;832.</td><td><a href=http://dx.doi.org/10.1038/89953>10.1038/89953</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Fern&#225;ndez-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis.<Emphasis Type="Italic">Liver Int</Emphasis>. 2004;24:477&#8211;483.</td><td><a href=http://dx.doi.org/10.1111/j.1478-3231.2004.0945.x>10.1111/j.1478-3231.2004.0945.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB<Subscript>2</Subscript> in the liver.<Emphasis Type="Italic">Gastroenterology</Emphasis>. 2005;128:742&#8211;755.</td><td><a href=http://dx.doi.org/10.1053/j.gastro.2004.12.050>10.1053/j.gastro.2004.12.050</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.<Emphasis Type="Italic">Nature</Emphasis>. 2005;434:782&#8211;786.</td><td><a href=http://dx.doi.org/10.1038/nature03389>10.1038/nature03389</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Maccarrone M, Attin&#224; M, Cartoni A, Bari M, Finazzi-Agric&#242; A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2001;76:594&#8211;601.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2001.00092.x>10.1046/j.1471-4159.2001.00092.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Petersen G, Moesgaard B, Schmid PC, et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2005;93:299&#8211;309.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2005.03013.x>10.1111/j.1471-4159.2005.03013.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Pagotto U, Marsicano G, Fezza F, et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level.<Emphasis Type="Italic">J Clin Endocrinol Metab</Emphasis>. 2001;86:2687&#8211;2696.</td><td><a href=http://dx.doi.org/10.1210/jc.86.6.2687>10.1210/jc.86.6.2687</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2005;65:1635&#8211;1641.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-3410>10.1158/0008-5472.CAN-04-3410</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Motobe T, Hashiguchi T, Uchimura T, et al. Endogenous cannbinoids are candidates for lipid mediators of bone cement implantation syndrome.<Emphasis Type="Italic">Shock</Emphasis>. 2004;21:8&#8211;12.</td><td><a href=http://dx.doi.org/10.1097/01.SHK.0000094766.36694.49>10.1097/01.SHK.0000094766.36694.49</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model.<Emphasis Type="Italic">FASEB J</Emphasis>. 2001;15:300&#8211;302.</td><td><a href=http://dx.doi.org/10.1096/fj.00-0399fje>10.1096/fj.00-0399fje</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Berrendero F, S&#225;nchez A, Cabranes A, et al. Changes in cannabinoid CB<Subscript>1</Subscript> receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.<Emphasis Type="Italic">Synapse</Emphasis>. 2001;41:195&#8211;202.</td><td><a href=http://dx.doi.org/10.1002/syn.1075>10.1002/syn.1075</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Cheng BC, Xu H, Calbay L, Pertwee RG, Coutts A, Forrester JV. Specific CB<Subscript>2</Subscript> receptor agonist suppresses the murine model of experimental autoimmune uveitis.<Emphasis Type="Italic">Invest Ophthalmol Vis Sci</Emphasis>. 2004;45:552.</td><td><a href=http://dx.doi.org/10.1167/iovs.03-0749>10.1167/iovs.03-0749</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Witting A, Weydt P, Hong S, Kliot M, M&#246;ller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1<Superscript>G93A</Superscript> transgenic mice.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2004;89:1555&#8211;1557.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02544.x>10.1111/j.1471-4159.2004.02544.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Benito C, Kim W-K, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2005;25:2530&#8211;2536.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.3923-04.2005>10.1523/JNEUROSCI.3923-04.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Adriani W, Caprioli A, Granstrem O, Carli M, Laviola G. The spontaneously hypertensive-rat as an animal model of ADHD evidence for impulsive and non-impulsive subpopulations.<Emphasis Type="Italic">Neurosci Biobehav Rev</Emphasis>. 2003;27:639&#8211;651.</td><td><a href=http://dx.doi.org/10.1016/j.neubiorev.2003.08.007>10.1016/j.neubiorev.2003.08.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson&#8217;s disease.<Emphasis Type="Italic">FASEB J</Emphasis>. 2000;14:1432&#8211;1438.</td><td><a href=http://dx.doi.org/10.1096/fj.14.10.1432>10.1096/fj.14.10.1432</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Gubellini P, Picconi B, Bari M, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2002;22:6900&#8211;6907.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2003;85:1018&#8211;1025.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2003.01759.x>10.1046/j.1471-4159.2003.01759.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2004;29:1134&#8211;1142.</td><td><a href=http://dx.doi.org/10.1038/sj.npp.1300407>10.1038/sj.npp.1300407</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2003;18:1607&#8211;1614.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9568.2003.02896.x>10.1046/j.1460-9568.2003.02896.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.<Emphasis Type="Italic">Brain Res</Emphasis>. 1991;547:267&#8211;274.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(91)90970-7>10.1016/0006-8993(91)90970-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Romero J, Berrendero F, P&#233;rez-Rosado A, et al. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB<Subscript>1</Subscript> receptor mRNA levels in the caudate-putamen.<Emphasis Type="Italic">Life Sci</Emphasis>. 2000;66:485&#8211;494.</td><td><a href=http://dx.doi.org/10.1016/S0024-3205(99)00618-9>10.1016/S0024-3205(99)00618-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Mailleux P, Vanderhaeghen J-J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study.<Emphasis Type="Italic">J Neurochem</Emphasis>. 1993;61:1705&#8211;1712.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.1993.tb09807.x>10.1111/j.1471-4159.1993.tb09807.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Zeng B-Y, Dass B, Owen A, et al. Chronic L-DOPA treatment increases striatal cannabinoid CB<Subscript>1</Subscript> receptor mRNA expression in 6-hydroxydopamine-lesioned rats.<Emphasis Type="Italic">Neurosci Lett</Emphasis>. 1999;276:71&#8211;74.</td><td><a href=http://dx.doi.org/10.1016/S0304-3940(99)00762-4>10.1016/S0304-3940(99)00762-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>McCaw EA, Hu H, Gomez GT, Hebb ALO, Kelly MEM, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (<Emphasis Type="Italic">CB1</Emphasis>) in Huntington&#8217;s disease transgenic mice.<Emphasis Type="Italic">Eur J Biochem</Emphasis>. 2004;271:4909&#8211;4920.</td><td><a href=http://dx.doi.org/10.1111/j.1432-1033.2004.04460.x>10.1111/j.1432-1033.2004.04460.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Page KJ, Besret L, Jain M, Monagham EM, Dunnett SB, Everitt BJ. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and &#956;-opioid receptor binding in the basal ganglia.<Emphasis Type="Italic">Exp Brain Res</Emphasis>. 2000;130:142&#8211;150.</td><td><a href=http://dx.doi.org/10.1007/s002210050016>10.1007/s002210050016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Lastres-Becker I, Fezza F, Cebeira M, et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington&#8217;s disease.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2001;12:2125&#8211;2129.</td><td><a href=http://dx.doi.org/10.1097/00001756-200107200-00017>10.1097/00001756-200107200-00017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fern&#225;ndez-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity<Emphasis Type="Italic">in vivo</Emphasis>.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2004;15:2375&#8211;2379.</td><td><a href=http://dx.doi.org/10.1097/00001756-200410250-00015>10.1097/00001756-200410250-00015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Lastres-Becker I, Hansen HH, Berrendero F, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington&#8217;s disease.<Emphasis Type="Italic">Synapse</Emphasis>. 2002;44:23&#8211;35.</td><td><a href=http://dx.doi.org/10.1002/syn.10054>10.1002/syn.10054</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Lastres-Becker I, Berrendero F, Lucas JJ, et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB<Subscript>1</Subscript> receptors in the basal ganglia of a transgenic model of Huntington&#8217;s disease.<Emphasis Type="Italic">Brain Res</Emphasis>. 2002;929:236&#8211;242.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(01)03403-5>10.1016/S0006-8993(01)03403-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Walker JM, Huang SM, Strangman NM, Tsou K, Sa&#241;udo-Pe&#241;a MC. Pain modulation by release of the endogenous cannabinoid anandamide.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1999;96:12198&#8211;12203.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.21.12198>10.1073/pnas.96.21.12198</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Lim G, Sung B, Ji R-R, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.<Emphasis Type="Italic">Pain</Emphasis>. 2003;105:275&#8211;283.</td><td><a href=http://dx.doi.org/10.1016/S0304-3959(03)00242-2>10.1016/S0304-3959(03)00242-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O&#8217;Donnell D. Induction of CB<Subscript>2</Subscript> receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2003;17:2750&#8211;2754.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9568.2003.02704.x>10.1046/j.1460-9568.2003.02704.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Dinis P, Charrua A, Avelino A, et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2004;24:11253&#8211;11263.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.2657-04.2004>10.1523/JNEUROSCI.2657-04.2004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake.<Emphasis Type="Italic">Nature</Emphasis>. 2001;410:822&#8211;825.</td><td><a href=http://dx.doi.org/10.1038/35071088>10.1038/35071088</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB<Subscript>1</Subscript> receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2003;63:908&#8211;914.</td><td><a href=http://dx.doi.org/10.1124/mol.63.4.908>10.1124/mol.63.4.908</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Maccarrone M, Fride E, Bisogno T, et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (<Emphasis Type="Italic">ob/ob</Emphasis>) mice and implications for fertility.<Emphasis Type="Italic">Mol Hum Reprod</Emphasis>. 2005;11:21&#8211;28.</td><td><a href=http://dx.doi.org/10.1093/molehr/gah130>10.1093/molehr/gah130</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2002;136:550&#8211;557.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0704767>10.1038/sj.bjp.0704767</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2005;30:508&#8211;515.</td><td><a href=http://dx.doi.org/10.1038/sj.npp.1300601>10.1038/sj.npp.1300601</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Patel S, Roelke CT, Rademacher DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2005;21:1057&#8211;1069.</td><td><a href=http://dx.doi.org/10.1111/j.1460-9568.2005.03916.x>10.1111/j.1460-9568.2005.03916.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR108</td><td>BibArticle</td><td>Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories.<Emphasis Type="Italic">Nature</Emphasis>. 2002;418:530&#8211;534.</td><td><a href=http://dx.doi.org/10.1038/nature00839>10.1038/nature00839</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR109</td><td>BibArticle</td><td>Liu P, Bilkey DK, Darlington CL, Smith PF. Cannabinoid CB<Subscript>1</Subscript> receptor protein expression in the rat hippocampus and entorhinal, perirhinal, postrhinal and temporal cortices: regional variations and agerelated changes.<Emphasis Type="Italic">Brain Res</Emphasis>. 2003;979:235&#8211;239.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(03)02872-5>10.1016/S0006-8993(03)02872-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2003;14:2209&#8211;2211.</td><td><a href=http://dx.doi.org/10.1097/00001756-200312020-00015>10.1097/00001756-200312020-00015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>B&#225;tkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.<Emphasis Type="Italic">Circulation</Emphasis>. 2004;110:1996&#8211;2002.</td><td><a href=http://dx.doi.org/10.1161/01.CIR.0000143230.23252.D2>10.1161/01.CIR.0000143230.23252.D2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Domenicali M, Ros J, Fern&#225;ndez-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors.<Emphasis Type="Italic">Gut</Emphasis>. 2005;54:522&#8211;527.</td><td><a href=http://dx.doi.org/10.1136/gut.2004.051599>10.1136/gut.2004.051599</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR113</td><td>BibArticle</td><td>Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension.<Emphasis Type="Italic">FASEB J</Emphasis>. 1998;12:1035&#8211;1044.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR114</td><td>BibArticle</td><td>Liu J, B&#225;tkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-&#954;B independently of platelet-activating factor.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2003;278:45034&#8211;45039.</td><td><a href=http://dx.doi.org/10.1074/jbc.M306062200>10.1074/jbc.M306062200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR115</td><td>BibArticle</td><td>Maccarrone M, De Petrocellis L, Bari M, et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.<Emphasis Type="Italic">Arch Biochem Biophys</Emphasis>. 2001;393:321&#8211;328.</td><td><a href=http://dx.doi.org/10.1006/abbi.2001.2500>10.1006/abbi.2001.2500</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR116</td><td>BibArticle</td><td>Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.<Emphasis Type="Italic">J Am Coll Cardiol</Emphasis>. 2001;38:2048&#8211;2054.</td><td><a href=http://dx.doi.org/10.1016/S0735-1097(01)01671-0>10.1016/S0735-1097(01)01671-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR117</td><td>BibArticle</td><td>Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB<Subscript>1</Subscript>-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2001;134:563&#8211;570.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0704293>10.1038/sj.bjp.0704293</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR118</td><td>BibArticle</td><td>Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation.<Emphasis Type="Italic">J Clin Invest</Emphasis>. 2004;113:1202&#8211;1209.</td><td><a href=http://dx.doi.org/10.1172/JCI200419465>10.1172/JCI200419465</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, Year, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR119</td><td>BibArticle</td><td>Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice.<Emphasis Type="Italic">Gastroenterology</Emphasis>. 2003;125:765&#8211;774.</td><td><a href=http://dx.doi.org/10.1016/S0016-5085(03)00892-8>10.1016/S0016-5085(03)00892-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR120</td><td>BibArticle</td><td>McVey DC, Schmid PC, Schmid HHO, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1).<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;304:713&#8211;722.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.043893>10.1124/jpet.102.043893</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR121</td><td>BibArticle</td><td>Mascolo N, Izzo AA, Ligresti A, et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice.<Emphasis Type="Italic">FASEB J</Emphasis>. 2002;16:U131-U51.</td><td><a href=http://dx.doi.org/10.1096/fj.02-0338fje>10.1096/fj.02-0338fje</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR122</td><td>BibArticle</td><td>Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB<Subscript>1</Subscript> cannabinoid receptor induction in experimental stroke.<Emphasis Type="Italic">Ann Neurol</Emphasis>. 2000;48:257&#8211;261.</td><td><a href=http://dx.doi.org/10.1002/1531-8249(200008)48:2&lt;257::AID-ANA18&gt;3.0.CO;2-P>10.1002/1531-8249(200008)48:2&lt;257::AID-ANA18&gt;3.0.CO;2-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR123</td><td>BibArticle</td><td>Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB<Subscript>1</Subscript> cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.<Emphasis Type="Italic">Neuroscience</Emphasis>. 2004;129:743&#8211;750.</td><td><a href=http://dx.doi.org/10.1016/j.neuroscience.2004.08.044>10.1016/j.neuroscience.2004.08.044</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR124</td><td>BibArticle</td><td>Kurabayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Maruyama I, Morishita Y. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver.<Emphasis Type="Italic">J Invest Surg</Emphasis>. 2005;18:25&#8211;31.</td><td><a href=http://dx.doi.org/10.1080/08941930590905189>10.1080/08941930590905189</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR125</td><td>BibArticle</td><td>Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during<Emphasis Type="Italic">in vivo</Emphasis> neurodegeneration.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2001;78:1415&#8211;1427.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2001.00542.x>10.1046/j.1471-4159.2001.00542.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR126</td><td>BibArticle</td><td>Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.<Emphasis Type="Italic">Nature</Emphasis>. 2001;413:527&#8211;531.</td><td><a href=http://dx.doi.org/10.1038/35097089>10.1038/35097089</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR127</td><td>BibArticle</td><td>Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2000;271:654&#8211;658.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2000.2686>10.1006/bbrc.2000.2686</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR128</td><td>BibArticle</td><td>Marsicano G, Goodenough S, Monory K, et al. CB<Subscript>1</Subscript> cannabinoid receptors and on-demand defense against excitotoxicity.<Emphasis Type="Italic">Science</Emphasis>. 2003;302:84&#8211;88.</td><td><a href=http://dx.doi.org/10.1126/science.1088208>10.1126/science.1088208</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR129</td><td>BibArticle</td><td>Chen K, Ratzliff A, Hilgenberg L, et al. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures.<Emphasis Type="Italic">Neuron</Emphasis>. 2003;39:599&#8211;611.</td><td><a href=http://dx.doi.org/10.1016/S0896-6273(03)00499-9>10.1016/S0896-6273(03)00499-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR130</td><td>BibArticle</td><td>Maccarrone M, Piccirilli S, Battista N, et al. Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2004;89:1293&#8211;1300.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02430.x>10.1111/j.1471-4159.2004.02430.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR131</td><td>BibArticle</td><td>S&#225;nchez C, de Ceballos ML, G&#243;mez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB<Subscript>2</Subscript> cannabinoid receptor.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2001;61:5784&#8211;5789.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR132</td><td>BibArticle</td><td>Burstein SH, Rossetti RG, Yagen B, Zurier RB. Oxidative metabolism of anandamide.<Emphasis Type="Italic">Prostaglandins Other Lipid Mediat</Emphasis>. 2000;61:29&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0090-6980(00)00053-8>10.1016/S0090-6980(00)00053-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR133</td><td>BibArticle</td><td>de Lago E, Ligresti A, Ortar G, et al. In vivo pharmacological actions of 2 novel inhibitors of anandamide cellular uptake.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;484:249&#8211;257.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.11.027>10.1016/j.ejphar.2003.11.027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR134</td><td>BibArticle</td><td>Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB. Regulation of anandamide tissue levels by<Emphasis Type="Italic">N</Emphasis>-arachidonylglycine.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2002;64:1147&#8211;1150.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(02)01301-1>10.1016/S0006-2952(02)01301-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR135</td><td>BibArticle</td><td>Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2001;98:9371&#8211;9376.</td><td><a href=http://dx.doi.org/10.1073/pnas.161191698>10.1073/pnas.161191698</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR136</td><td>BibArticle</td><td>Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia.<Emphasis Type="Italic">Pain</Emphasis>. 2004;109:319&#8211;327.</td><td><a href=http://dx.doi.org/10.1016/j.pain.2004.01.022>10.1016/j.pain.2004.01.022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR137</td><td>BibArticle</td><td>Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2004;101:10821&#8211;10826.</td><td><a href=http://dx.doi.org/10.1073/pnas.0401292101>10.1073/pnas.0401292101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR138</td><td>BibArticle</td><td>Martin BR, Lichtman AH. Cannabinoid transmission and pain perception.<Emphasis Type="Italic">Neurobiol Dis</Emphasis>. 1998;5:447&#8211;461.</td><td><a href=http://dx.doi.org/10.1006/nbdi.1998.0218>10.1006/nbdi.1998.0218</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR139</td><td>BibArticle</td><td>Pertwee RG. Cannabinoid receptors and pain.<Emphasis Type="Italic">Prog Neurobiol</Emphasis>. 2001;63:569&#8211;611.</td><td><a href=http://dx.doi.org/10.1016/S0301-0082(00)00031-9>10.1016/S0301-0082(00)00031-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR140</td><td>BibChapter</td><td>Walker JM, Hohman AG. Cannabinoid mechanisms of pain suppression. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacolology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:509&#8211;54.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR141</td><td>BibArticle</td><td>Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of<Emphasis Type="Italic">R</Emphasis>(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.<Emphasis Type="Italic">Neurosci Lett</Emphasis>. 1997;221:157&#8211;160.</td><td><a href=http://dx.doi.org/10.1016/S0304-3940(96)13308-5>10.1016/S0304-3940(96)13308-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR142</td><td>BibArticle</td><td>Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1996;7:593&#8211;596.</td><td><a href=http://dx.doi.org/10.1097/00001756-199601310-00052>10.1097/00001756-199601310-00052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR143</td><td>BibArticle</td><td>Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.<Emphasis Type="Italic">J Neurosci</Emphasis>. 1998;18:451&#8211;457.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR144</td><td>BibArticle</td><td>Dogrul A, Gardell LR, Ma S, Ossipov MH, Porreca F, Lai J. &#8216;Knock-down&#8217; of spinal CB<Subscript>1</Subscript> receptors produces abnormal pain and elevates spinal dynorphin content in mice.<Emphasis Type="Italic">Pain</Emphasis>. 2002;100:203&#8211;209.</td><td><a href=http://dx.doi.org/10.1016/S0304-3959(02)00302-0>10.1016/S0304-3959(02)00302-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR145</td><td>BibArticle</td><td>Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB<Subscript>1</Subscript> receptors.<Emphasis Type="Italic">Eur J Neurosci</Emphasis>. 2000;12:533&#8211;539.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9568.2000.00929.x>10.1046/j.1460-9568.2000.00929.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR146</td><td>BibArticle</td><td>Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB<Subscript>2</Subscript> cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2003;100:10529&#8211;10533.</td><td><a href=http://dx.doi.org/10.1073/pnas.1834309100>10.1073/pnas.1834309100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR147</td><td>BibArticle</td><td>Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB<Subscript>1</Subscript> receptor knockout mice.<Emphasis Type="Italic">Science</Emphasis>. 1999;283:401&#8211;404.</td><td><a href=http://dx.doi.org/10.1126/science.283.5400.401>10.1126/science.283.5400.401</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR148</td><td>BibArticle</td><td>Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB<Subscript>1</Subscript> receptor knockout mice.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1999;96:5780&#8211;5785.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.10.5780>10.1073/pnas.96.10.5780</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR149</td><td>BibArticle</td><td>Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB<Subscript>2</Subscript>, a peripheral cannabinoid receptor.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1999;96:14228&#8211;14233.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.25.14228>10.1073/pnas.96.25.14228</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR150</td><td>BibArticle</td><td>Clayton N, Marshall FH, Bountra C, O&#8217;Shaughnessy CT. CB<Subscript>1</Subscript> and CB<Subscript>2</Subscript> cannabinoid receptors are implicated in inflammatory pain.<Emphasis Type="Italic">Pain</Emphasis>. 2002;96:253&#8211;260.</td><td><a href=http://dx.doi.org/10.1016/S0304-3959(01)00454-7>10.1016/S0304-3959(01)00454-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR151</td><td>BibArticle</td><td>Valenzano KJ, Tafesse L, Lee G, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW 405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.<Emphasis Type="Italic">Neuropharmacology</Emphasis>. 2005;48:658&#8211;672.</td><td><a href=http://dx.doi.org/10.1016/j.neuropharm.2004.12.008>10.1016/j.neuropharm.2004.12.008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR152</td><td>BibArticle</td><td>Malan TP, Ibrahim MM, Deng H, et al. CB<Subscript>2</Subscript> cannabinoid receptor-mediated peripheral antinociception.<Emphasis Type="Italic">Pain</Emphasis>. 2001;93:239&#8211;245.</td><td><a href=http://dx.doi.org/10.1016/S0304-3959(01)00321-9>10.1016/S0304-3959(01)00321-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR153</td><td>BibArticle</td><td>Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB<Subscript>2</Subscript> receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation.<Emphasis Type="Italic">Neuroscience</Emphasis>. 2003;119:747&#8211;757.</td><td><a href=http://dx.doi.org/10.1016/S0306-4522(03)00126-X>10.1016/S0306-4522(03)00126-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR154</td><td>BibArticle</td><td>Quartilho A, Mata HP, Ibrahim MM, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB<Subscript>2</Subscript> cannabinoid receptors.<Emphasis Type="Italic">Anesthesiology</Emphasis>. 2003;99:955&#8211;960.</td><td><a href=http://dx.doi.org/10.1097/00000542-200310000-00031>10.1097/00000542-200310000-00031</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR155</td><td>BibArticle</td><td>Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB<Subscript>2</Subscript> receptors suppresses hyperalgesia evoked by intradermal capsaicin.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;308:446&#8211;453.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.060079>10.1124/jpet.103.060079</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR156</td><td>BibArticle</td><td>Ibrahim MM, Porreca F, Lai J, et al. CB<Subscript>2</Subscript> cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2005;102:3093&#8211;3098.</td><td><a href=http://dx.doi.org/10.1073/pnas.0409888102>10.1073/pnas.0409888102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR157</td><td>BibArticle</td><td>Ross RA, Coutts AA, McFarlane SM, et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception.<Emphasis Type="Italic">Neuropharmacology</Emphasis>. 2001;40:221&#8211;232.</td><td><a href=http://dx.doi.org/10.1016/S0028-3908(00)00135-0>10.1016/S0028-3908(00)00135-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR158</td><td>BibArticle</td><td>Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.<Emphasis Type="Italic">Br J Pharmacol</Emphasis>. 2005;146:467&#8211;476.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0706348>10.1038/sj.bjp.0706348</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR159</td><td>BibArticle</td><td>Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids.<Emphasis Type="Italic">Nature</Emphasis>. 1998;394:277&#8211;281.</td><td><a href=http://dx.doi.org/10.1038/28393>10.1038/28393</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR160</td><td>BibArticle</td><td>Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;396:85&#8211;92.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(00)00226-0>10.1016/S0014-2999(00)00226-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR161</td><td>BibArticle</td><td>Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 &#8216;N of 1&#8217; studies.<Emphasis Type="Italic">Anaesthesia</Emphasis>. 2004;59:440&#8211;452.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2044.2004.03674.x>10.1111/j.1365-2044.2004.03674.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR162</td><td>BibArticle</td><td>Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1975;15:139&#8211;143.</td><td><a href=http://dx.doi.org/10.1002/j.1552-4604.1975.tb02348.x>10.1002/j.1552-4604.1975.tb02348.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Year, FirstPage, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR163</td><td>BibArticle</td><td>Noyes R, Brunk SF, Avery DH, Canter A. Analgesic properties of delta-9-tetrahydrocannabinol and codeine.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1975;18:84&#8211;89.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/cpt197518184>10.1002/cpt197518184</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR164</td><td>BibArticle</td><td>Pertwee RG. Cannabinoids and multiple sclerosis<Emphasis Type="Italic">Pharmacol Ther</Emphasis>. 2002;95:165&#8211;174.</td><td><a href=http://dx.doi.org/10.1016/S0163-7258(02)00255-3>10.1016/S0163-7258(02)00255-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR165</td><td>BibArticle</td><td>Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.<Emphasis Type="Italic">Clin Rehabil</Emphasis>. 2003;17:21&#8211;29.</td><td><a href=http://dx.doi.org/10.1191/0269215503cr581oa>10.1191/0269215503cr581oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR166</td><td>BibArticle</td><td>Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.<Emphasis Type="Italic">Lancet</Emphasis>. 2003;362:1517&#8211;1526.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(03)14738-1>10.1016/S0140-6736(03)14738-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR167</td><td>BibArticle</td><td>Gauter B, Rukwied R, Konrad C. Cannabinoid agonists in the treatment of blepharospasm&#8212;a case report study.<Emphasis Type="Italic">Neuroendocrinol Lett</Emphasis>. 2004;25:45&#8211;48.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR168</td><td>BibArticle</td><td>Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.<Emphasis Type="Italic">Mult Scler</Emphasis>. 2004;10:425&#8211;433.</td><td><a href=http://dx.doi.org/10.1191/1352458504ms1063oa>10.1191/1352458504ms1063oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR169</td><td>BibArticle</td><td>Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial.<Emphasis Type="Italic">BMJ</Emphasis>. 2004;329:253&#8211;257.</td><td><a href=http://dx.doi.org/10.1136/bmj.38149.566979.AE>10.1136/bmj.38149.566979.AE</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR170</td><td>BibArticle</td><td>Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB<Subscript>2</Subscript> receptor.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;296:420&#8211;425.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR171</td><td>BibArticle</td><td>Lavey BJ, Kozlowski JA, Hipkin RW, et al. Triaryl bis-sulfones as a new class of cannabinoid CB<Subscript>2</Subscript> receptor inhibitors: identification of a lead and initial SAR studies.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2005;15:783&#8211;786.</td><td><a href=http://dx.doi.org/10.1016/j.bmcl.2004.11.007>10.1016/j.bmcl.2004.11.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR172</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lunn</span> <span style='background:#DDDDDD'>CA</span></span></aug>. Immune modulation by cannabinoids: targetting the cannabinoid &lt;Subscript&gt;CB2&lt;/Subscript&gt; receptor. Symposium on cannabinoid receptors: pharmacological opportunities for obesity and inflammation: New York Academy of Sciences, 2004. <span style='background:#FFFF0F'>Available at: http://www.nyas.org/ebriefreps/main.asp?intSubsectionID-1406 (Accessed)</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR173</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Costa</span> <span style='background:#DDDDDD'>B</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Colleoni</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Trovato</span> <span style='background:#DDDDDD'>AE</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Comelli</span> <span style='background:#DDDDDD'>F</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Franke</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Giognoni</span> <span style='background:#DDDDDD'>G.</span></span></aug> <span style='background:#CCCCFF'>Anandamide transport and hydrolysis as targets for the treatment of neuropathic pain: Effects of AM404 and URB597 in rats with chronic constriction injury of the sciatic nerve. 2005 Symposium on the Cannabinoids; June 24&#8211;27; Clearwater Beach, FL. Burlington, VT: International Cannabinoid Research</span> <span style='background:#CCFF99'>Society</span>; <span style='background:#66FF66'>2005</span>:<span style='background:#D279FF'>33</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR174</td><td>BibArticle</td><td>Mestre L, Correa F, Ar&#233;valo-Martin A, et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2005;92:1327&#8211;1339.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02979.x>10.1111/j.1471-4159.2004.02979.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR175</td><td>BibArticle</td><td>Pryce G, Ahmed Z, Hankey DJR, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.<Emphasis Type="Italic">Brain</Emphasis>. 2003;126:2191&#8211;2202.</td><td><a href=http://dx.doi.org/10.1093/brain/awg224>10.1093/brain/awg224</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR176</td><td>BibArticle</td><td>Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model.<Emphasis Type="Italic">Nature</Emphasis>. 2000;404:84&#8211;87.</td><td><a href=http://dx.doi.org/10.1038/35003583>10.1038/35003583</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR177</td><td>BibArticle</td><td>Brooks JW, Pryce G, Bisogno T, et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB<Subscript>1</Subscript>/CB<Subscript>2</Subscript> receptors.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2002;439:83&#8211;92.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(02)01369-9>10.1016/S0014-2999(02)01369-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR178</td><td>BibArticle</td><td>Wilkinson JD, Whalley BJ, Baker D, et al. Medicinal cannabis: is {ieE653-1} necessary for all its effects?.<Emphasis Type="Italic">J Pharm Pharmacol</Emphasis>. 2003;55:1687&#8211;1694.</td><td><a href=http://dx.doi.org/10.1211/0022357022304>10.1211/0022357022304</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR179</td><td>BibArticle</td><td>Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. {ieE653-2} a novel treatment for experimental autoimmune encephalomyelitis.<Emphasis Type="Italic">J Neuroimmunol</Emphasis>. 1989;23:73&#8211;81.</td><td><a href=http://dx.doi.org/10.1016/0165-5728(89)90075-1>10.1016/0165-5728(89)90075-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR180</td><td>BibArticle</td><td>Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids.<Emphasis Type="Italic">Immunopharmacology</Emphasis>. 1994;28:209&#8211;214.</td><td><a href=http://dx.doi.org/10.1016/0162-3109(94)90056-6>10.1016/0162-3109(94)90056-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR181</td><td>BibArticle</td><td>Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid<Emphasis Type="Italic">R</Emphasis>(+)WIN55,212.<Emphasis Type="Italic">J Clin Invest</Emphasis>. 2003;111:1231&#8211;1240.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR182</td><td>BibArticle</td><td>Ar&#233;valo-Martin N, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2003;23:2511&#8211;2516.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR183</td><td>BibArticle</td><td>Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.<Emphasis Type="Italic">Mult Scler</Emphasis>. 2004;10:417&#8211;424.</td><td><a href=http://dx.doi.org/10.1191/1352458504ms1048oa>10.1191/1352458504ms1048oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR184</td><td>BibArticle</td><td>Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.<Emphasis Type="Italic">Mult Scler</Emphasis>. 2004;10:434&#8211;441.</td><td><a href=http://dx.doi.org/10.1191/1352458504ms1082oa>10.1191/1352458504ms1082oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR185</td><td>BibArticle</td><td>Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.<Emphasis Type="Italic">Neurology</Emphasis>. 2002;58:1404&#8211;1407.</td><td><a href=http://dx.doi.org/10.1212/WNL.58.9.1404>10.1212/WNL.58.9.1404</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, JournalTitle, ArticleTitle, Year, FirstPage, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR186</td><td>BibArticle</td><td>Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.<Emphasis Type="Italic">FASEB J</Emphasis>. 2004;18:U320-U33.</td><td><a href=http://dx.doi.org/10.1096/fj.04-1754fje>10.1096/fj.04-1754fje</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR187</td><td>BibArticle</td><td>Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of<Emphasis Type="Italic">ras</Emphasis> oncogene-dependent tumor growth.<Emphasis Type="Italic">FASEB J</Emphasis>. 2001;15:U100-U16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR188</td><td>BibArticle</td><td>Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research.<Emphasis Type="Italic">Nat Med</Emphasis>. 2002;8:547&#8211;550.</td><td><a href=http://dx.doi.org/10.1038/nm0602-547>10.1038/nm0602-547</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR189</td><td>BibArticle</td><td>Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB<Subscript>1</Subscript> receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis.<Emphasis Type="Italic">FASEB J</Emphasis>. 2003;17:U458-U74.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1096/fj.02-1129fje>10.1096/fj.02-1129fje</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year</td><td>CrossRef</td></tr><tr><td>CR190</td><td>BibArticle</td><td>Guzm&#225;n M. Cannabinoids: potential anticancer agents.<Emphasis Type="Italic">Nat Rev Cancer</Emphasis>. 2003;3:745&#8211;755.</td><td><a href=http://dx.doi.org/10.1038/nrc1188>10.1038/nrc1188</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR191</td><td>BibChapter</td><td>Guzm&#225;n M. Effects on cell viability In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids Handbook of Experimental Pharmacolology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:627&#8211;642.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR192</td><td>BibChapter</td><td>Izzo AA, Coutts AA. Cannabinoids and the digestive tract. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacolology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:573&#8211;598.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR193</td><td>BibArticle</td><td>Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. CB<Subscript>1</Subscript> cannabinoid receptors are involved in neuroprotection via NF-&#954;B inhibition.<Emphasis Type="Italic">J Cereb Blood Flow Metab</Emphasis>. 2005;25:477&#8211;484.</td><td><a href=http://dx.doi.org/10.1038/sj.jcbfm.9600047>10.1038/sj.jcbfm.9600047</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR194</td><td>BibArticle</td><td>El Banoua F, Caraballo I, Flores JA, Galan-Rodriguez B, Fernandez-Espejo E. Effects on turning of microinjections into basal ganglia of D<Subscript>1</Subscript> and D<Subscript>2</Subscript> dopamine receptors agonists and the cannabinoid CB<Subscript>1</Subscript> antagonist SR 141716A in a rat Parkinson&#8217;s model.<Emphasis Type="Italic">Neurobiol Dis</Emphasis>. 2004;16:377&#8211;385.</td><td><a href=http://dx.doi.org/10.1016/j.nbd.2004.03.002>10.1016/j.nbd.2004.03.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR195</td><td>BibArticle</td><td>Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, et al. Cannabinoid CB<Subscript>1</Subscript> antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism.<Emphasis Type="Italic">Neurobiol Dis</Emphasis>. 2005;18:591&#8211;601.</td><td><a href=http://dx.doi.org/10.1016/j.nbd.2004.10.015>10.1016/j.nbd.2004.10.015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR196</td><td>BibArticle</td><td>Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2001;156:79&#8211;85.</td><td><a href=http://dx.doi.org/10.1007/s002130100728>10.1007/s002130100728</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR197</td><td>BibArticle</td><td>Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G. Activation of peripheral CB<Subscript>1</Subscript> cannabinoid receptors in haemorrhagic shock.<Emphasis Type="Italic">Nature</Emphasis>. 1997;390:518&#8211;521.</td><td><a href=http://dx.doi.org/10.1038/37371>10.1038/37371</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR198</td><td>BibArticle</td><td>Kadoi Y, Hinohara H, Kunimoto F, Kuwano H, Saito S, Goto F. Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats.<Emphasis Type="Italic">Br J Anaesth</Emphasis>. 2005;94:563&#8211;568.</td><td><a href=http://dx.doi.org/10.1093/bja/aei106>10.1093/bja/aei106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR199</td><td>BibChapter</td><td>Robson PJ. Human studies of cannabinoids and medicinal cannabis. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook Exp Pharmacol</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005:719&#8211;756.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR200</td><td>BibChapter</td><td>Robson PJ, Guy GW. Clinical studies of cannabis-based medicines. In: Guy GW, Whittle BA, Robson PJ, eds.<Emphasis Type="Italic">The Medicinal Uses of Cannabis and Cannabinoids</Emphasis>. London, UK: Pharmaceutical Press; 2005:229&#8211;269.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR201</td><td>BibArticle</td><td>Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis.<Emphasis Type="Italic">Eur Neurol</Emphasis> 1997;38:44&#8211;48.</td><td><a href=http://dx.doi.org/10.1159/000112901>10.1159/000112901</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR202</td><td>BibArticle</td><td>Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey.<Emphasis Type="Italic">Int J Clin Pract</Emphasis>. 2005;59:291&#8211;295.</td><td><a href=http://dx.doi.org/10.1111/j.1742-1241.2004.00271.x>10.1111/j.1742-1241.2004.00271.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR203</td><td>BibArticle</td><td>De Vry J, Denzer D, Reissmueller E, et al. 3-[2-cyano-3-(trifluoro methyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid CB<Subscript>1</Subscript>/CB<Subscript>2</Subscript> receptor partial agonist with antihyperalgesic and antiallodynic effects.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;310:620&#8211;632.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.062836>10.1124/jpet.103.062836</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR204</td><td>BibArticle</td><td>Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin.<Emphasis Type="Italic">Pain</Emphasis>. 2003;102:283&#8211;288.</td><td><a href=http://dx.doi.org/10.1016/S0304-3959(02)00401-3>10.1016/S0304-3959(02)00401-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR205</td><td>BibArticle</td><td>Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine-induced responses are attenuated by a cannabinoid receptor agonist in human skin.<Emphasis Type="Italic">Inflamm Res</Emphasis>. 2003;52:238&#8211;245.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR206</td><td>BibArticle</td><td>Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics.<Emphasis Type="Italic">Life Sci</Emphasis>. 2004;74:1317&#8211;1324.</td><td><a href=http://dx.doi.org/10.1016/j.lfs.2003.09.038>10.1016/j.lfs.2003.09.038</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR207</td><td>BibArticle</td><td>Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever.<Emphasis Type="Italic">Anaesthesia</Emphasis>. 1997;52:483&#8211;488.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2044.1997.139-az0132.x>10.1111/j.1365-2044.1997.139-az0132.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR208</td><td>BibChapter</td><td>Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V, ed.<Emphasis Type="Italic">Cannabinoids</Emphasis>. New York, NY: Kluwer Academic/Plenum Publishers; 2004:32&#8211;83.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/9781118451281>10.1002/9781118451281</a></td><td><b>CrossRef-Meta</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR209</td><td>BibArticle</td><td>Mendelson WB, Basile AS. The hypnotic actions of the fatty acid amide, oleamide.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2001;25:S36-S39.</td><td><a href=http://dx.doi.org/10.1016/S0893-133X(01)00341-4>10.1016/S0893-133X(01)00341-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR210</td><td>BibArticle</td><td>Pertwee RG, Ross RA. Cannabinoid receptors and their ligands.<Emphasis Type="Italic">Prostaglandins Leukot Essent Fatty Acids</Emphasis>. 2002;66:101&#8211;121.</td><td><a href=http://dx.doi.org/10.1054/plef.2001.0341>10.1054/plef.2001.0341</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR211</td><td>BibArticle</td><td>Sim-Selley LJ. Regulation of cannabinoid CB<Subscript>1</Subscript> receptors in the central nervous system by chronic cannabinoids.<Emphasis Type="Italic">Crit Rev Neurobiol</Emphasis>. 2003;15:91&#8211;119.</td><td><a href=http://dx.doi.org/10.1615/CritRevNeurobiol.v15.i2.10>10.1615/CritRevNeurobiol.v15.i2.10</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR212</td><td>BibChapter</td><td>Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. In: Pertwee RG, ed.<Emphasis Type="Italic">Cannabinoids, Handbook of Experimental Pharmacolology</Emphasis>. Heidelberg, Germany: Springer-Verlag; 2005;168:691&#8211;717.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR213</td><td>BibArticle</td><td>De Vry J, Jentzsch KR, Kuhl E, Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.<Emphasis Type="Italic">Behav Pharmacol</Emphasis>. 2004;15:1&#8211;12.</td><td><a href=http://dx.doi.org/10.1097/00008877-200402000-00001>10.1097/00008877-200402000-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR214</td><td>BibArticle</td><td>Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation.<Emphasis Type="Italic">Chem Phys Lipids</Emphasis>. 2000;108:211&#8211;220.</td><td><a href=http://dx.doi.org/10.1016/S0009-3084(00)00197-3>10.1016/S0009-3084(00)00197-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR215</td><td>BibArticle</td><td>Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.<Emphasis Type="Italic">Lancet</Emphasis>. 2005;365:1389&#8211;1397.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(05)66374-X>10.1016/S0140-6736(05)66374-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR216</td><td>BibArticle</td><td>Idris AI, van&#8217;t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.<Emphasis Type="Italic">Nat Med</Emphasis>. 2005;11:774&#8211;779.</td><td><a href=http://dx.doi.org/10.1038/nm1255>10.1038/nm1255</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR217</td><td>BibBook</td><td>Brown AJ, Ueno S, Suen K, Dowell SJ, Wise A Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. Symposium on the Cannabinoids; June 24&#8211;27; Clearwater Beach, FL. Burlington, VT: International Cannabinoid Research Society; 2005, 16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR218</td><td>BibBook</td><td>Sj&#246;gren S, Ryberg E, Lindblom A, et al. A new receptor for cannabinoid ligands Symposium on the Cannabinoids; June 24&#8211;27; Clearwater Beach, FL. Burlington, VT: International Cannabinoid Research Society; 2005, 106.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR219</td><td>BibArticle</td><td>Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia.<Emphasis Type="Italic">Nature</Emphasis>. 2005;435:1108&#8211;1112.</td><td><a href=http://dx.doi.org/10.1038/nature03658>10.1038/nature03658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>